Point of Care Nano-Technology, Inc. (PCNT) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Point of Care Nano-Technology, Inc. (PCNT) stock?
Point of Care Nano-Technology, Inc. (PCNT) no longer trades on public markets. The figures below are historical and are not a current quote.
Beta 0.82: the stock has moved about 18% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Point of Care Nano-Technology, Inc. (PCNT). Point of Care Nano-Technology, Inc. is a biotechnology company formerly focused on saliva-based diagnostics, now seeking new opportunities in the life sciences. The company currently does not have significant operations. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for PCNT: PCNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PCNT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 32 months old (Jan 1, 2024), so the figures and score below describe that period, not today.
PCNT: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Point of Care Nano-Technology, Inc. (PCNT) Healthcare & Pipeline Overview
Point of Care Nano-Technology, Inc., previously engaged in saliva-based diagnostics, is currently exploring new ventures within the life sciences industry. With a market capitalization of $0.00B and trading on the OTC market, the company seeks to redefine its operational focus and establish a sustainable business model in a competitive sector.
What Is the Investment Thesis for PCNT?
Point of Care Nano-Technology, Inc. presents a speculative investment opportunity, primarily driven by its intention to pursue new ventures in the life sciences. With a current market capitalization of $0.00B and a negative P/E ratio of -0.10, the company's valuation is highly dependent on its ability to successfully identify and capitalize on new business opportunities. Key value drivers include the potential for strategic acquisitions, partnerships, or the development of novel technologies. The company's beta of 0.82 suggests a slightly lower volatility compared to the market. However, the absence of current operations introduces significant risk. Successful execution of a new business plan and securing necessary funding are critical for future growth. Investors should carefully consider the high level of uncertainty and speculative nature of this investment.
Based on FMP financials and quantitative analysis
PCNT Key Highlights
Market Cap: $0.00B indicates a micro-cap company with limited assets and operations.
- P/E Ratio: -0.10 reflects negative earnings, suggesting the company is not currently profitable.
- Beta: 0.82 indicates the stock is slightly less volatile than the market average.
- Dividend Yield: None, as the company does not currently offer dividends, typical for companies in a turnaround phase.
- OTC Other Tier: Indicates a high-risk investment due to limited regulation and disclosure requirements.
Who Are PCNT's Competitors?
PCNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELVAY Evolva Holding S.A. | $1.16 | 0.00% | — | |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are PCNT's Key Strengths?
Experienced management team.
- Historical expertise in point-of-care diagnostics.
- Potential for innovation in the life sciences.
- Publicly traded company structure.
What Are PCNT's Weaknesses?
Lack of current operations and revenue generation.
- Limited financial resources.
- Dependence on identifying and executing new business opportunities.
- High level of uncertainty and speculative nature.
What Could Drive PCNT Stock Higher?
Announcement of new business ventures in the life sciences (timeline unknown).
- Potential strategic acquisitions or partnerships (timeline unknown).
- Securing funding for new initiatives (timeline unknown).
What Are the Key Risks for PCNT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Lack of current operations and revenue generation.
- Failure to identify and execute successful new ventures.
- Intense competition in the biotechnology sector.
- Regulatory hurdles and lengthy approval processes.
- Limited financial resources and high level of uncertainty.
What Are the Growth Opportunities for PCNT?
- Expansion into Personalized Medicine: The personalized medicine market is experiencing substantial growth, driven by advancements in genomics and diagnostics. By leveraging its expertise in point-of-care diagnostics, Point of Care Nano-Technology, Inc. could develop personalized diagnostic tools and therapies tailored to individual patient needs.
- Strategic Acquisitions in the Life Sciences: Point of Care Nano-Technology, Inc. could pursue strategic acquisitions of companies with complementary technologies or products in the life sciences sector. This approach would allow the company to rapidly expand its portfolio and enter new markets. The timeline for such acquisitions would depend on the availability of suitable targets and the company's ability to secure financing. Successful acquisitions could significantly enhance the company's growth prospects and market position.
- Development of Novel Diagnostic Technologies: Investing in the research and development of novel diagnostic technologies represents a significant growth opportunity for Point of Care Nano-Technology, Inc. By focusing on innovative approaches, such as nanotechnology-based diagnostics or advanced biosensors, the company could gain a competitive edge in the market. The timeline for developing and commercializing new technologies is typically several years, requiring sustained investment and strategic partnerships.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop and commercialize diagnostic tools for specific therapies represents another growth avenue. By partnering with established players in the pharmaceutical industry, Point of Care Nano-Technology, Inc. can leverage their resources and expertise to accelerate the development and adoption of its products. These partnerships can provide access to new markets and revenue streams, contributing to the company's long-term growth.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, offers significant growth potential for Point of Care Nano-Technology, Inc. These markets are experiencing rapid growth in healthcare spending and demand for advanced diagnostic technologies. By establishing a presence in these regions, the company can tap into new customer bases and diversify its revenue streams. The timeline for geographic expansion would depend on regulatory approvals and the establishment of distribution networks.
What Are PCNT's Competitive Advantages?
- Historical expertise in saliva-based diagnostics (currently not operational).
- Potential for intellectual property development in new ventures.
- Management's experience in the biotechnology sector.
What Does PCNT Do?
Point of Care Nano-Technology, Inc., incorporated in 2010 and based in Davenport, Florida, initially focused on developing and manufacturing saliva-based medical diagnostic products. Founded as Unique Growing Solutions, Inc., the company rebranded to Point of Care Nano-Technology, Inc. in March 2015, signaling a strategic shift towards point-of-care diagnostics. However, the company currently does not have significant operations. The company's history reflects an attempt to innovate in the medical diagnostics field, specifically targeting non-invasive methods through saliva-based testing. Despite this initial focus, Point of Care Nano-Technology, Inc. is now actively pursuing new business opportunities within the broader life sciences industry, indicating a pivot from its original product line. The company’s current strategy involves identifying and capitalizing on emerging trends and technologies within the life sciences sector, aiming to establish a sustainable and profitable business model. The success of this transition will depend on its ability to secure funding, develop strategic partnerships, and execute its new business plan effectively.
What Products and Services Does PCNT Offer?
- Formerly developed saliva-based medical diagnostic products.
- Currently seeking new business opportunities in the life sciences industry.
- Aims to innovate in the medical diagnostics field.
- Focuses on non-invasive diagnostic methods.
- Intends to capitalize on emerging trends and technologies.
- Plans to establish a sustainable and profitable business model.
How Does PCNT Make Money?
- Historically focused on developing and manufacturing saliva-based diagnostic products.
- Currently exploring strategic acquisitions and partnerships in the life sciences.
- Future revenue generation dependent on successful new business ventures.
What Industry Does PCNT Operate In?
Point of Care Nano-Technology, Inc. operates within the biotechnology sector, a dynamic and competitive industry characterized by rapid innovation and high regulatory hurdles. The company's competitors include ALSE (ALSE), CNBI (CNBI), ELVAY (ELVAY), GNOW (GNOW), and HCYTD (HCYTD). These companies are involved in various aspects of biotechnology, from drug discovery to diagnostics. Point of Care Nano-Technology, Inc.'s success will depend on its ability to differentiate itself and carve out a niche in this competitive landscape.
Who Are PCNT's Key Customers?
- Historically targeted healthcare providers and diagnostic laboratories.
- Future customer base dependent on new business opportunities in the life sciences.
- Potential customers include pharmaceutical companies and research institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● Latest filing 627 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 38 |
| 2026-08-24 | 38 |
| 2026-08-25 | 38 |
| 2026-08-26 | 38 |
What changed?
The score has stayed at 38.
Over the same 3 days the stock moved +0.0%.
Point of Care Nano-Technology, Inc. Financial Trajectory
Point of Care Nano-Technology, Inc. (PCNT) reported $0 in revenue for Q3 FY2024, based on the latest filing compared to the prior quarter. The company recorded a net loss of $5K, with diluted EPS of $-0.01.
Company Profile
Point of Care Nano-Technology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Davenport, US. The company is led by CEO Raouf Guirguis. PCNT has traded publicly since 2012.
Key Financial Metrics
Return on equity for Point of Care Nano-Technology, Inc. stands at 155.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Point of Care Nano-Technology, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PCNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Experienced management team.
- Historical expertise in point-of-care diagnostics.
- Potential for innovation in the life sciences.
- Publicly traded company structure.
Bear Case
- Lack of current operations and revenue generation.
- Limited financial resources.
- Dependence on identifying and executing new business opportunities.
- High level of uncertainty and speculative nature.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2024 | $0 | -$4,979 | -$0.01 |
| Q2 FY2024 | $0 | $6,308 | $0.01 |
Q3 FY2024 · filed 23 Dec 2024 · SEC EDGAR →
Based on FMP financials and quantitative analysis
PCNT Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Dec 20, 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 17, 2019
Leadership: Raouf Guirguis
CEO
Raouf Guirguis serves as the Chief Executive Officer of Point of Care Nano-Technology, Inc. His background includes experience in the biotechnology and pharmaceutical industries, with a focus on strategic planning and business development. He has held various leadership positions in companies involved in drug discovery, diagnostics, and healthcare services. Guirguis's expertise spans across multiple areas, including product development, regulatory affairs, and commercialization. He holds advanced degrees in science and business administration, providing a strong foundation for his role in leading Point of Care Nano-Technology, Inc.
Track Record: Under Raouf Guirguis's leadership, Point of Care Nano-Technology, Inc. has focused on identifying and pursuing new business opportunities in the life sciences. Key strategic decisions include the exploration of potential acquisitions, partnerships, and the development of novel technologies. While the company currently does not have significant operations, Guirguis's efforts are directed towards establishing a sustainable and profitable business model. His track record reflects a commitment to innovation and strategic growth in the biotechnology sector.
PCNT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and may not be subject to regular audits or reporting requirements. Investing in OTC Other companies carries significant risk due to the lack of transparency and potential for fraud or manipulation. These companies may also have limited trading volume and liquidity, making it difficult to buy or sell shares.
- OTC Tier: OTC Other
- Limited or no financial disclosure increases the risk of fraud or mismanagement.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- OTC Other companies may not meet minimum listing standards, indicating potential financial instability.
- The company's lack of current operations adds further uncertainty and risk.
- Dependence on identifying and executing new business opportunities is highly speculative.
- Verify the company's legal standing and registration.
- Attempt to obtain any available financial statements, even if unaudited.
- Research the background and experience of the management team.
- Assess the company's plans for future operations and funding.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Publicly traded company structure provides some level of regulatory oversight.
- Experienced management team with a background in biotechnology.
- Company's stated intention to pursue new business opportunities in the life sciences.
- Historical operations in the medical diagnostics field.
Point of Care Nano-Technology, Inc. Healthcare Stock: Key Questions Answered
What happened to Point of Care Nano-Technology, Inc. (PCNT) stock?
Point of Care Nano-Technology, Inc. (PCNT) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy PCNT shares?
No. PCNT stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for PCNT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PCNT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Point of Care Nano-Technology, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Point of Care Nano-Technology, Inc. do?
Point of Care Nano-Technology, Inc. previously focused on developing and manufacturing saliva-based medical diagnostic products. However, the company currently does not have significant operations.
What do analysts say about PCNT stock?
There is currently no analyst coverage available for Point of Care Nano-Technology, Inc. due to its limited operations and speculative nature. Investors should conduct their own thorough research and consider the high level of risk associated with this investment.
What are the main risks for PCNT?
The primary risks for Point of Care Nano-Technology, Inc. include its lack of current operations and revenue generation, dependence on identifying and executing successful new ventures, intense competition in the biotechnology sector, regulatory hurdles and lengthy approval processes, and limited financial resources.
What are the key growth opportunities for PCNT in healthcare?
Point of Care Nano-Technology, Inc.'s growth opportunities in healthcare lie in expanding into personalized medicine, developing novel diagnostic technologies, and forming strategic partnerships with pharmaceutical companies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data and company statements.
- The company's future prospects are highly speculative and dependent on successful execution of new business ventures.
- Analyst coverage is currently unavailable.